Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerizationBROZZO, Maurice S; BJELIC, Sasa; KISKO, Kaisa et al.Blood. 2012, Vol 119, Num 7, pp 1781-1788, issn 0006-4971, 8 p.Article

Engraftment and Reconstitution of Hematopoiesis Is Dependent on VEGFR2-Mediated Regeneration of Sinusoidal Endothelial CellsHOOPER, Andrea T; BUTLER, Jason M; JAMES, Daylon et al.Cell stem cell. 2009, Vol 4, Num 3, pp 263-274, issn 1934-5909, 12 p.Article

A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. CommentaryJINUSHI, Masahisa; DRANOFF, Glenn; EMENS, Leisha A et al.Clinical cancer research. 2007, Vol 13, Num 13, issn 1078-0432, 3762-3764, 3951-3959 [12 p.]Article

Phase I Evaluation of CDP791, a PEGylated Di-Fab' Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2TON, N. C; PARKER, G. J. M; POWER, F et al.Clinical cancer research. 2007, Vol 13, Num 23, pp 7113-7118, issn 1078-0432, 6 p.Article

Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2MITOLA, Stefania; RAVELLI, Cosetta; MORONI, Emanuela et al.Blood. 2010, Vol 116, Num 18, pp 3677-3680, issn 0006-4971, 4 p.Article

CD 146 is a coreceptor for VEGFR-2 in tumor angiogenesisTIANXIA JIANG; JIE ZHUANG; JING FENG et al.Blood. 2012, Vol 120, Num 11, pp 2330-2339, issn 0006-4971, 10 p.Article

Review : Monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapyYOUSSOUFIAN, Hagop; HICKLIN, Daniel J; ROWINSKY, Eric K et al.Clinical cancer research. 2007, Vol 13, Num 18, issn 1078-0432, 5544s-5548s, 2Conference Paper

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumorsTONG, Ricky T; BOUCHER, Yves; KOZIN, Sergey V et al.Cancer research (Baltimore). 2004, Vol 64, Num 11, pp 3731-3736, issn 0008-5472, 6 p.Article

NANOG induction of fetal liver kinase-1 (FLK1) transcription regulates endothelial cell proliferation and angiogenesisKOHLER, Erin E; COWAN, Colleen E; CHATTERJEE, Ishita et al.Blood. 2011, Vol 117, Num 5, pp 1761-1769, issn 0006-4971, 9 p.Article

Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human FibronectinTOLCHER, Anthony W; SWEENEY, Christopher J; EATON, Cheryl et al.Clinical cancer research (Print). 2011, Vol 17, Num 2, pp 363-371, issn 1078-0432, 9 p.Article

Notch signaling regulates tumor angiogenesis by diverse mechanismsDUFRAINE, J; FUNAHASHI, Y; KITAJEWSKI, J et al.Oncogene (Basingstoke). 2008, Vol 27, Num 38, pp 5132-5137, issn 0950-9232, 6 p.Article

YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine klinase inhibitor, has highly potent antitumor activity against established tumorsAMINO, Nobuaki; IDEYAMA, Yukitaka; SHIBASAKI, Masayuki et al.Clinical cancer research. 2006, Vol 12, Num 5, pp 1630-1638, issn 1078-0432, 9 p.Article

The Sphingosine-1-Phosphate Receptor S1PR1 Restricts Sprouting Angiogenesis by Regulating the Interplay between VE-Cadherin and VEGFR2GAENGEL, Konstantin; NIAUDET, Colin; PANG, Mei-Fong et al.Developmental cell. 2012, Vol 23, Num 3, pp 587-599, issn 1534-5807, 13 p.Article

Regulation of vascular endothelial growth factor receptor 2 trafficking and angiogenesis by Golgi localized t-SNARE syntaxin 6MANICKAM, Venkatraman; TIWARI, Ajit; JUNG, Jae-Joon et al.Blood. 2011, Vol 117, Num 4, pp 1425-1435, issn 0006-4971, 11 p.Article

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy¹BEEBE, Jean S; JANI, Jitesh P; ATHERTON, Jim et al.Cancer research (Baltimore). 2003, Vol 63, Num 21, pp 7301-7309, issn 0008-5472, 9 p.Article

Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathwayMYUNG HWAN JUNG; SUN HEE LEE; AHN, Eun-Mi et al.Carcinogenesis (New York. Print). 2009, Vol 30, Num 4, pp 655-661, issn 0143-3334, 7 p.Article

Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2WADA, Satoshi; TSUNODA, Takuya; BABA, Toshiyuki et al.Cancer research (Baltimore). 2005, Vol 65, Num 11, pp 4939-4946, issn 0008-5472, 8 p.Article

Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formationHEFFELFINGER, Sue C; MEI YAN; GEAR, Robin B et al.Laboratory investigation. 2004, Vol 84, Num 8, pp 989-998, issn 0023-6837, 10 p.Article

Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38LAMALICE, Laurent; HOULE, Francois; JOURDAN, Guillaume et al.Oncogene (Basingstoke). 2004, Vol 23, Num 2, pp 434-445, issn 0950-9232, 12 p.Article

Selective Stimulation of VEGFR2 Accelerates Progressive Renal DiseaseSATO, Waichi; TANABE, Katsuyuki; NAKAGAWA, Takahiko et al.The American journal of pathology. 2011, Vol 179, Num 1, pp 155-166, issn 0002-9440, 12 p.Article

Down-regulation of Vascular Endothelial Growth Factor Receptor 2 Is a Major Molecular Determinant of Proteasome Inhibitor―Mediated Antiangiogenic Action in Endothelial CellsMEISSNER, Markus; REICHENBACH, Gabi; STEIN, Monika et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 5, pp 1976-1984, issn 0008-5472, 9 p.Article

Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2ROBERTS, Nicole; KLOOS, Bryan; CASSELLA, Melanie et al.Cancer research (Baltimore). 2006, Vol 66, Num 5, pp 2650-2657, issn 0008-5472, 8 p.Article

Vascular endothelial growth factor receptor-2: Its unique signaling and specific ligand, VEGF-ESHIBUYA, Masabumi.Cancer science. 2003, Vol 94, Num 9, pp 751-756, issn 1347-9032, 6 p.Article

c-Cbl inhibits angiogenesis and tumor growth by suppressing activation of PLCγ1MEYER, R. D; HUSAIN, D; RAHIMI, N et al.Oncogene (Basingstoke). 2011, Vol 30, Num 19, pp 2198-2206, issn 0950-9232, 9 p.Article

Delphinidin, a dietary anthocyanidin, inhibits vascular endothelial growth factor receptor-2 phosphorylationLAMY, Sylvie; BLANCHETTE, Mélanie; MICHAUD-LEVESQUE, Jonathan et al.Carcinogenesis (New York. Print). 2006, Vol 27, Num 5, pp 989-996, issn 0143-3334, 8 p.Article